Literature DB >> 10763997

Hearing results in pediatric patients with chronic otitis media after ossicular reconstruction with partial ossicular replacement prostheses and total ossicular replacement prostheses.

T P Murphy.   

Abstract

OBJECTIVE: To examine hearing results in pediatric patients after ossicular reconstruction with partial ossicular replacement prostheses (PORPs) and total ossicular replacement prostheses (TORPs) in children with chronic otitis media.
METHODS: A retrospective chart review was performed on 55 pediatric patients with chronic otitis media who underwent ossicular reconstruction from 1991 to 1998. Patients' audiograms were evaluated preoperatively and postoperatively for pure-tone average (PTA), air-bone gap (ABG), speech reception threshold (SRT), method of ossicular reconstruction, and management of the mastoid.
RESULTS: Twenty-seven patients underwent ossicular reconstruction with TORPs. The average preoperative ABG was 40.1 dB, and the average postoperative ABG was 31.6 dB. Forty-one percent of the children improved their PTA greater than 10 dB postoperatively, and 52% of children did not change their ABG by more than 10 dB postoperatively. Nineteen percent of children with TORPs had a postoperative ABG less than 20 dB, and 44% of children with TORPs had a postoperative ABG less than 30 dB. Twenty-eight patients underwent ossicular reconstruction with PORPs. The average preoperative ABG was 29.7 dB, and the average postoperative ABG was 22.5 dB. Thirty-two percent of patients improved their PTA by greater than 10 dB, while 57% of children with PORPs did not change their ABG by more than 10 dB postoperatively. Forty-three percent of children with PORPs had an ABG of less than 20 dB postoperatively, and 71% of children with PORPs had a postoperative ABG less than or equal to 30 dB.
CONCLUSIONS: Children who underwent ossicular reconstruction with PORPs had slightly better postoperative hearing than did children with TORPs. Postoperative hearing was essentially unchanged in approximately 55% of both groups. Preoperative hearing levels may be the most important factor determining postoperative hearing in nonstaged surgery for children with chronic otitis media Long-term hearing results in children with single-stage surgery were not as good as those reported in the literature for staged surgery. Severe mucosal disease and eustachian tube dysfunction may contribute to poorer hearing results in children.

Entities:  

Mesh:

Year:  2000        PMID: 10763997     DOI: 10.1097/00005537-200004000-00005

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

1.  Comparison of incus interpositioning technique versus glass ionomer cement application in type 2 tympanoplasty.

Authors:  Haşmet Yazıcı; Hakkı Uzunkulaoğlu; Hatice Karadas Emir; Zeynep Kızılkaya; Sedat Doğan; Erdal Samim
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-08-04       Impact factor: 2.503

2.  Biocompatible Nanocomposite Implant with Silver Nanoparticles for Otology-In Vivo Evaluation.

Authors:  Magdalena Ziąbka; Elżbieta Menaszek; Jacek Tarasiuk; Sebastian Wroński
Journal:  Nanomaterials (Basel)       Date:  2018-09-27       Impact factor: 5.076

3.  Impact of the demographic and aetiological factors and intraoperative findings on postoperative outcomes in chronic otitis media surgery

Authors:  Süleyman Cebeci; Mehmet Suat Özbilen; Ismet Bayramoğlu; Yusuf Kemal Kemaloğlu; Kadir Kemal Uygur; Yildirim Ahmet Bayazit; Recep Karamert
Journal:  Turk J Med Sci       Date:  2020-02-13       Impact factor: 0.973

4.  Determinants of Change in Air-Bone Gap and Bone Conduction in Patients Operated on for Chronic Otitis Media.

Authors:  Maciej Wiatr; Agnieszka Wiatr; Jacek Składzień; Paweł Stręk
Journal:  Med Sci Monit       Date:  2015-08-11

5.  Usefulness of a ventilation tube as a partial ossicular replacement prosthesis (PORP) in ossiculoplasty in patients with chronic otitis media.

Authors:  Maciej Wiatr; Jacek Składzień; Jerzy Tomik; Paweł Stręk
Journal:  Med Sci Monit       Date:  2014-06-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.